Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through...
/PRNewswire/ -- The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years....
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE...
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022...
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...